The COVID-19 pandemic fundamentally disrupted healthcare delivery across the globe. For the estimated 537 million adults living with diabetes worldwide, the crisis introduced unique barriers: canceled routine appointments, delayed lab visits, reduced access to in-person endocrinologists, and heightened anxiety about viral exposure. Yet amid these difficulties, the Internet of Things (IoT) emerged not just as a stopgap but as a transformative force that reshaped diabetes management. By enabling continuous, remote, and data-driven care, IoT technologies have helped patients maintain glycemic control while minimizing infection risk. This article explores how IoT devices — including continuous glucose monitors, smart insulin pens, and connected wearables — are changing the landscape of diabetes care during the pandemic and what the future holds for remote chronic disease management.

Understanding IoT in Healthcare

The Internet of Things refers to a network of physical devices embedded with sensors, software, and connectivity that allows them to collect and exchange data. In healthcare, this translates into a digital ecosystem where medical devices no longer operate in isolation. Instead, they communicate with smartphones, cloud platforms, and electronic health record systems to provide real-time insights into a patient’s health status.

In the specific context of diabetes, IoT devices serve three core functions: sensing (measuring glucose, activity, or insulin delivery), transmitting (sending data over Bluetooth, Wi-Fi, or cellular networks), and analyzing (processing data on cloud servers or edge devices to generate alerts, trends, and recommendations). This triad has made it possible for patients and providers to move beyond episodic, clinic-based care toward continuous, home-based management — a critical shift during a pandemic that limited in-person interactions.

Key categories of IoT devices in diabetes include:

  • Continuous Glucose Monitors (CGMs) – Sensors placed subcutaneously that measure interstitial glucose every 1–5 minutes, transmitting data to a receiver or smartphone app.
  • Smart Insulin Pens – Pen injectors that record dose, time, and type of insulin, often syncing with an app to help track cumulative doses.
  • Connected Blood Glucose Meters – Traditional fingerstick meters that automatically upload readings to a cloud platform.
  • Wearable Fitness Trackers – Devices that monitor physical activity, heart rate, and sleep, offering context that helps explain glucose fluctuations.
  • Insulin Pumps with Closed-Loop Capabilities – Advanced systems that integrate CGM data to automatically adjust basal insulin delivery, often referred to as artificial pancreas systems.

How IoT Is Enhancing Diabetes Management During the Pandemic

Real-Time Blood Glucose Monitoring Reduces Exposure Risk

Before the pandemic, many individuals with diabetes relied primarily on self-monitoring of blood glucose through fingerstick tests. While effective, this approach provided only snapshot readings and required patients to log results manually — often leading to incomplete or delayed data sharing with clinicians. CGMs changed this paradigm. Devices such as the Dexcom G6, Abbott FreeStyle Libre 2, and Medtronic Guardian Connect continuously measure glucose levels and transmit data wirelessly. During COVID-19, this real-time capability became invaluable.

Patients no longer had to visit clinics for HbA1c tests or routine glucose checks. Instead, providers could review CGM data remotely through secure dashboards. The Dexcom Clarity platform, for example, allows physicians to access time-in-range statistics, hypoglycemia patterns, and daily glucose traces without requiring a single office visit. Studies published during the pandemic confirmed that patients using CGMs maintained or even improved their glucose control despite lockdowns. A 2020 study in Diabetes Care found that CGM users experienced no significant deterioration in glycemic metrics during the first wave of COVID-19, underscoring the device’s stabilizing role.

Remote Patient Monitoring Enables Safer Consultations

Remote patient monitoring (RPM) combines IoT data collection with telehealth consultation. During the pandemic, as clinics shuttered or limited in-person visits, RPM became a lifeline. Patients with diabetes could upload CGM data, blood pressure readings, and activity levels to a platform that their care team could review before or during a virtual visit. This allowed clinicians to adjust medication doses, recommend lifestyle changes, and identify nascent issues — all without physical contact.

For diabetes care, RPM has proven especially effective for identifying dangerous trends. Cloud-based alarms can notify both patients and clinicians about prolonged hyperglycemia, rapid glucose drops, or sensor dislodgement. In many health systems, nurse-led monitoring teams triage alerts and intervene proactively. A review in Journal of Diabetes Science and Technology highlighted that RPM programs during COVID-19 reduced hospitalization rates and emergency department visits among high-risk diabetes patients. The technology effectively bridged the care gap created by social distancing.

Integration with Telemedicine Platforms

IoT devices also integrate seamlessly with telemedicine systems. Many electronic health record (EHR) vendors now offer APIs that pull CGM data directly into the patient chart, giving physicians a comprehensive view during a video consultation. This integration eliminates the need for patients to manually send screenshots or PDFs — a step that was common early in the pandemic and often introduced errors. Direct data ingestion ensures that the clinician sees the most current, accurate information. For example, the integration between Dexcom and Epic’s MyChart allows patients to share glucose data with their provider through a simple consent process. This synergy between IoT and telehealth has become a standard care model that is likely to outlast the pandemic.

Enhanced Data Analytics and Artificial Intelligence

The real power of IoT in diabetes management lies not just in data collection but in analysis. Machine learning algorithms applied to CGM data can detect patterns that even experienced clinicians might miss. For example, an AI model can correlate glucose spikes with specific meal times, exercise habits, or insulin dose timings, generating personalized recommendations. Some systems also predict hypoglycemia up to 30 minutes in advance, giving patients time to take corrective action. The Medtronic Guardian 4 system, for instance, uses a predictive algorithm that suspends insulin delivery when a low glucose level is forecast, reducing the risk of severe hypoglycemic events.

During the pandemic, these analytical capabilities became especially important because patients were experiencing unprecedented lifestyle changes: altered meal routines, reduced physical activity due to lockdowns, and increased stress — all of which affect blood glucose. IoT platforms that could learn and adapt to each individual’s new baseline helped patients avoid dangerous excursions. The U.K.’s National Health Service reported that flash glucose monitoring with data analytics improved glucose control in type 1 diabetes patients during the pandemic, with a significant reduction in hospital admissions for diabetic ketoacidosis.

Benefits of IoT-Based Diabetes Management During COVID-19

The pandemic accelerated the adoption of IoT in diabetes care, and the benefits have been well documented. Beyond the obvious advantage of reducing infection risk, several key outcomes emerged:

Improved Glycemic Control

Continuous monitoring provides a far richer data set than fingerstick tests. Patients and clinicians can see not just the highs and lows but also the duration, timing, and patterns. This visibility leads to better-informed insulin dosing and lifestyle adjustments. Systematic reviews show that CGM use correlates with a reduction in HbA1c of 0.5–1.0% and an increase in time-in-range. During the pandemic, these improvements were sustained even as face-to-face support diminished.

Reduced Hospitalizations and Emergency Visits

IoT alerts catch dangerous trends early. Remote monitoring programs have been associated with a 30–50% reduction in diabetes-related emergency department visits. For example, Kaiser Permanente reported that its RPM program for type 2 diabetes patients reduced inpatient admissions by 30% during the pandemic’s peak months. Fewer hospital visits meant lower risk of COVID-19 exposure and less strain on overwhelmed healthcare systems.

Increased Patient Engagement and Self-Efficacy

IoT devices put real-time feedback in the patient’s hands. The dashboard visualizations, trend arrows, and alerts empower individuals to take proactive steps. Many CGM apps also include social sharing features, allowing users to share data with family members or diabetes educators, fostering a support network. Qualitative studies have found that patients feel more in control of their condition when they can see the immediate impact of their choices.

Timely Interventions During Lockdowns

When lockdowns restricted movement, IoT enabled care continuity. A patient experiencing a prolonged hyperglycemic episode could receive a phone call from a nurse within hours, not weeks. Automated alerts could even prompt insulin adjustments through a prescribed algorithm. For individuals with type 1 diabetes, this responsiveness significantly reduced the risk of diabetic ketoacidosis — a serious complication that spiked in some regions during the pandemic because of delayed care.

Challenges and Limitations of IoT in Diabetes Care

Despite its promise, IoT adoption in diabetes is not without hurdles. The pandemic highlighted several critical barriers that must be addressed to ensure equitable access.

Data Privacy and Security

IoT devices generate a constant stream of highly personal health data. This information must be transmitted and stored securely to prevent breaches. While HIPAA in the United States and GDPR in Europe impose strict requirements, not all device manufacturers adhere to the highest security standards. Patients also must manage consent and data-sharing preferences carefully. During the rapid expansion of telehealth early in the pandemic, some security protocols were relaxed, raising concerns about data integrity. Moving forward, robust encryption, end-to-end security, and transparent data governance will be essential.

Device Affordability and Access

Cost remains a major barrier. CGMs can cost hundreds of dollars per month without insurance coverage, and smart insulin pens often require a premium. In many lower-income countries, even basic blood glucose test strips are beyond reach. The pandemic exacerbated existing health disparities; patients in underserved communities were less likely to have access to IoT devices, reliable internet, or smartphones. Without policy intervention, the digital divide in diabetes care may widen. Medicare and some private insurers have expanded coverage for CGMs during the pandemic, but global access remains limited.

Reliable Internet Connectivity

IoT devices depend on consistent connectivity to upload data and receive software updates. In rural areas or regions with poor cellular coverage, data transmission may fail, leaving providers with gaps in information. Some CGMs offer limited offline storage, but many features — especially remote monitoring and cloud analytics — require a stable connection. The pandemic underscored the need for infrastructure investment to support digital health.

Regulatory and Reimbursement Hurdles

Not all IoT diabetes devices have received regulatory approval for remote monitoring indications. In some countries, telehealth reimbursement for remote data review is still limited. Clinicians may not be compensated for time spent analyzing CGM data outside of a formal visit, creating a disincentive for adoption. The pandemic prompted temporary waivers, but permanent changes to reimbursement structures are needed to sustain IoT use.

User Training and Health Literacy

Effectively using IoT devices requires a certain level of technical proficiency. Older adults and those with low digital literacy may struggle to set up sensors, interpret trend graphs, or respond to alerts. Manufacturers have improved user interfaces, but training and ongoing support must be provided. The Cleveland Clinic, for example, deployed diabetes educators to conduct virtual onboarding sessions for new CGM users during the pandemic, which improved retention and satisfaction.

The Future of IoT in Diabetes Management

The pandemic has permanently altered expectations for chronic disease care. Patients and providers alike have experienced the convenience and effectiveness of remote monitoring, and many are unlikely to revert entirely to in-person visits. The future of IoT in diabetes management is bright, driven by several converging trends.

Closed-Loop Systems and Artificial Pancreas

The ultimate IoT vision for diabetes is a fully automated closed-loop system that combines a CGM, an insulin pump, and a control algorithm to manage blood glucose without manual input. Several such systems — often called artificial pancreas systems — have received regulatory approval. Medtronic’s MiniMed 780G, Tandem’s Control-IQ, and the Tidepool Loop are already used widely. These systems reduce the cognitive load on patients and improve glycemic outcomes. Future versions will integrate additional sensors, such as continuous ketone monitors, to further enhance safety.

Predictive Analytics and Personalized Care

AI and machine learning will become even more deeply embedded in IoT platforms. Instead of just reacting to current glucose values, systems will forecast trends hours ahead and suggest preemptive actions. Personalized algorithms that learn a patient’s unique metabolic responses will fine-tune insulin delivery and lifestyle advice. The FDA’s Digital Health Center of Excellence is actively promoting the development of such tools, paving the way for regulatory frameworks that can keep pace with innovation.

Cost Reduction and Broader Access

As manufacturing scales up and competition increases, the cost of IoT devices is expected to fall. Implantable CGMs (such as the Eversense) that last up to 180 days may reduce the per-day cost. Non-invasive glucose sensors — using light or electromagnetic waves — remain in development and could eventually eliminate the need for transcutaneous sensors altogether. The World Health Organization has identified digital health as a key enabler of universal health coverage, and its guidance encourages countries to invest in connected health technologies for chronic diseases.

Integration with Broader Digital Health Ecosystems

IoT diabetes devices will increasingly connect with other health data sources — electronic health records, pharmacy records, wearables, and even smart home devices. A holistic view of a patient’s health — including activity, sleep, stress, and food intake — will enable truly personalized diabetes management. Platforms like Apple Health and Google Fit are already aggregating this data, and the interoperability standards (such as FHIR) are maturing. The pandemic accelerated the adoption of these interoperable platforms, and the momentum is likely to continue.

Mental Health and Behavioral Support

Diabetes management is as much a psychological challenge as a physiological one. IoT devices that provide encouraging feedback, gamification, and connection to peer support networks can improve adherence. Some CGMs now feature “community” modes where users can share anonymized data to learn from others. Incorporating behavioral science into device design — such as nudging users toward healthier choices — will become a standard feature. The pandemic’s toll on mental health has made these features more important than ever.

Conclusion

The COVID-19 pandemic served as a powerful catalyst for the adoption of IoT technologies in diabetes management. What began as a necessity — to safely provide care under lockdown — has evolved into a robust, effective, and increasingly indispensable model of chronic disease management. Continuous glucose monitors, smart insulin pens, and remote monitoring platforms have proven their worth in maintaining glycemic control, reducing hospital visits, and empowering patients. While challenges around cost, equity, data privacy, and connectivity remain, the trajectory is clear: the future of diabetes care is digital, connected, and patient-centered. As technology continues to advance and become more affordable, IoT will not only mitigate the effects of future public health crises but also fundamentally improve the daily lives of millions living with diabetes.